The strategy of JKphArma Galenic Innovation is based on the rapid development of existing active principles, using new galenic forms enabling administration via the per-mucous sub-lingual route or the per-mucous gingivo-jugal route.
All of our clinical developments follow the same programme :
Dose-ranging study to establish/validate the dose: our technological innovation must make it possible to reduce the required dose of the active ingredient when compared to existing drugs under usual oral dosages.
biodisponibilité study to validate efficacy (24 subjects).
Tolerance study to demonstrate/establish the tolerance of our new galenic form (40 to 50 patients in single-arm trials) : our technological innovation based on dose reduction and administration via the per-mucous buccal or gingivo-jugal route must make it possible to improve tolerance.